<DOC>
	<DOCNO>NCT02850692</DOCNO>
	<brief_summary>Cystic fibrosis affect organ lung . Liver disease affect 30 % patient : main manifestation development portal hypertension ( PHT ) . The pathophysiology comorbidity still poorly understood . It previously consider secondary formation biliary cirrhosis another hypothesis would primitive pathology venous vessel may cause gradual emergence portal hypertension without cirrhosis . Evidence indiscutly suggest cystic fibrosis associate specific endothelial dysfunction , especially CFTR ( Cystic Fibrosis Transmembrane conductance Regulator ) protein express surface endothelial cell . The investigator hypothesize liver disease relate PHT−associated cystic fibrosis associate systemic endothelial dysfunction . The aim : To demonstrate systemic endothelial dysfunction patient cystic fibrosis associate PHT . To study correlation measure systemic endothelial function serum marker endothelial dysfunction measure liver stiffness systemic endothelial function .</brief_summary>
	<brief_title>Portal Hypertension Systemic Endothelial Function</brief_title>
	<detailed_description>Prospective , monocentric study , four group patient : - Patients cystic fibrosis PHT - Cystic fibrosis patient without PHT - Patients free cystic fibrosis PHT cause - Healthy control . One study visit , follow-up . During visit follow examination perform : - Collection blood sample 21 mL . - Liver eElastography achieve hardware FibroScan® - - Measurement endothelial function Endopat® - Contrast−enhanced tomography . Abdominal CT scan perform healthy volunteer .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<criteria>Patients 18 year . Patients affiliate social security scheme Patients give write consent Four study group : Group A : Patients cystic fibrosis ( CF ) liver damage diagnosis CF base sweat test genetic analysis ) . PHT diagnosis base tomographic criterion portal vein width superior &gt; 15 mm , portosystemic shunt / splenomegaly Group B : cystic fibrosis patient without PHT diagnosis base sweat test genetic analysis ) . Absence PHTP predicate tomographic Scanner . Group C : Patients free CF PHT relate another cause . Patients follow viral liver disease ( hepatitis B C ) idiopathic portal venous system disorder , without cirrhosis . The diagnosis PHT base tomographic criterion portal vein width superior &gt; 15 mm , highlight portosystemic shunt , splenomegaly ) / indirect sign namely ascitis esophageal varix . Group D : Healthy control . Patients suffer uncontrolled hypertension despite treatment ( systolic BP &gt; 160 mmHg ) ; Patient uncontrolled diabetes ( glycated Hb measurement do last 3 month &gt; 7 % ) ; Patients uncorrected dyslipidemia ; Patient suffer sleep apnea syndrome ; Patients severe coagulation disorder : PR &lt; 50 % , platelet &lt; 70,000 / microL , current anticoagulant treatment ; Patient contraindication injection iodinate contrast material , include history hypersensitivity iodinate contrast medium renal clearance failure &lt; 50 ml / min MDRD formula Patients allergic latex contraindicate endothelial function measurement ; Acute pathology unresolved time inclusion : respiratory exacerbation , ongoing infection , recent thrombosis ; Smoking history &gt; 10 packyears ; Vasoactive therapy may interfere measurement endothelial function stop 24 hour measurement : nitrate , betablockers , angiotensin convert enzyme inhibitor , calcium channel blocker , inhibitor endothelin receptor , similar prostacyclin analog , inhibitor phosphodiesterases ; Pregnant lactate woman ( patient childbearing potential include βHCG urine test negative ; Patient unable provide write consent . Patient guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>